Regeneron's (REGN) Eylea has been approved by FDA
Importance
Level 1
- EYLEA HD® Approved by FDA as First and Only Injectable Anti-VEGF With Dosing Intervals up to 5 Months for Wet Age-Related Macular Degeneration and Diabetic Macular Edema
#REGENERON PHARMACEUTICALS INC#REGN.US#FDA#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#REGN#US EQUITIES